| anti-MPO GPA | anti-PR3 GPA | anti-MPO MPA | anti-PR3 MPA | |
|---|---|---|---|---|
| (n=20) | (n=74) | (n=43) | MPA (n=13) | |
| Male % | 35 | 54 | 67 | 54 |
| Renal involvement % | 75 | 61 | 88 | 92 |
| Ear-nose-throat involvement % | 65 | 77 | 12 | 0 |
| Lung involvement % | 70 | 80 | 70 | 31 |
| Skin involvement % | 25 | 30 | 21 | 38 |
| Neurological involvement % | 45 | 24 | 23 | 31 |
| Rheumatologic involvement % | 55 | 62 | 37 | 54 |
| Limited vasculitis, % | 40 | 23 | 12 | 23 |
| Relapse % | 50 | 50 | 21 | 8 |
| Death % | 0 | 23 | 19 | 31 |
| Initial BVAS, median ± SD | 20±7.2 | 18.5±7.4 | 17±5.1 | 15±7.5 |
| Age at diagnosis (years), median ± SD | 66.5±11 | 60±17 | 62±13 | 70±21 |
| Follow-up (months), median ± SD | 49±47 | 55±65 | 50±37 | 33±108 |